A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen.
There have been conflicting data in literature about the value of Phyllanthus amarus in treating hepatitis B virus-related disorders. To evaluate the role of Phyllanthus amarus in eradication of the virus in hepatitis B carriers. Phyllanthus amarus was administered to 30 asymptomatic carriers of hepatitis B surface antigen (HBsAg) in a dosage of 250 to 500 mg thrice daily for 4 to 8 weeks. None of the 30 subjects cleared HBsAg. Phyllanthus amarus was well tolerated, with no clinical side effects or changes in the organ profiles for safety evaluation. Phyllanthus amarus is not effective in clearing HBsAg in asymptomatic carriers of the antigen.